Genmab — November 2019

[Sukkeralf]

E L its a bit strange the way Genmab writes that - no need to put focus on late breaker abstracts if you did not have a chance for that

[E_L]

yes, agree. but like you, I wouldn't know what it could be. BCMA/CD3 would definately be nice surprise!

[Sukkeralf]

Otherwise it could be dara in something - AML/MDS maybe

[Bulder]

Would be a bit of a surprise, as LBs are not just ordinary abstracts, but "outstanding studies".

[bibob]

May they keep an abstrct " secret " until LB. ??

[Sukkeralf]

Agree Bulder

[Sukkeralf]

bibob - deadline for late breaker was in october

[Sukkeralf]

So at least not secret to the ASH commitee

[Bulder]

Only 6 abs will be selected.

[Bulder]

bibob, they not only "may", they must keep it as a secret, as data are embargoed until publication.

[Solsen]

Foreløbig ny ATH i dag med 1519 kr

[bibob]

Thx Bulder and Sukker.

[Sukkeralf]

Måske data fra dette studie:

[Sukkeralf]

(clinicaltrials.gov)

[Sukkeralf]

Næh ikke alligevel - der kommer en poster fra dette studie

[Solsen]

CD20/CD3 er vel stadig en mulighed ?

[E_L]

i doubt it as they already have an oral presentation? (which i am already happy with..)

[Solsen]

BCMA/CD3 is my guess then

[E_L]

I am gonna feel reallly guilty now if they don't get a late breaker after starting this

[Solsen]

I belive the BCMA/CD3 duobody could be highly effective in responses and together with Dara we could have a drug combi that could put Revlimid aside. Just dreaming perhaps.